Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study

Mov Disord. 2017 Sep;32(9):1335-1336. doi: 10.1002/mds.27092. Epub 2017 Jun 24.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amantadine / adverse effects
  • Anticonvulsants / therapeutic use*
  • Antiparkinson Agents / adverse effects
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Dyskinesia, Drug-Induced / drug therapy*
  • Dyskinesia, Drug-Induced / etiology
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Parkinson Disease / drug therapy
  • Seveso Accidental Release
  • Topiramate / therapeutic use*
  • Treatment Outcome

Substances

  • Anticonvulsants
  • Antiparkinson Agents
  • Topiramate
  • Amantadine